Skip to main content
. 2016 Jul 6;34(4):191–198. doi: 10.1111/1755-5922.12183

Figure 2.

Figure 2

Mean (±SD) levels of (A) plasma aldosterone, (B) plasma endothelin‐1 and (C and D) plasma and urine NT‐proBNP for patients receiving LCZ696 treatment. Data are presented as geometric mean and 95% confidence intervals; *< 0.05. NT‐proBNP, N‐terminal pro‐hormone B‐type natriuretic peptide; SD, standard deviation.